Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.5, and our video podcast, CANCER BUZZ TV.
Home / Operational Pathways for Molecular Testing in NSCLC / Operational Pathways for Molecular Testing in NSCLC Overview

Operational Pathways for Molecular Testing in NSCLC Overview

As the role of molecular testing in the diagnosis and treatment planning for non-small cell lung cancer (NSCLC) continues to expand, the efficiency and timeliness of molecular testing processes are an increasing concern for cancer care providers, cancer programs, and oncology practices. Guideline-driven molecular testing for patients with NSCLC informs the subtype of lung cancer, development of the treatment plan, and prognosis. Lack of clarity on operational and care pathways for molecular testing may contribute to inefficiencies and delays that can affect treatment initiation or act as barriers to patient access to testing and the potential to benefit from precision treatments requiring companion diagnostic tests.

Consideration of operational pathways for molecular testing in NSCLC is a potential avenue to improve standardization of institutional, care team, and provider processes for molecular testing, to increase timeliness of care, and to reduce overall costs through multidisciplinary team understanding of guideline recommendations and currently available tests for patients with NSCLC, improved consistency of utilization of molecular testing results to inform treatment planning and shared decision-making, and development of processes for ongoing evaluation of molecular testing protocols and institutional care pathways.

Through this educational program, ACCC will identify and disseminate examples of effective practices and tools for developing, implementing, and assessing operational pathways for molecular testing for eligible patients with NSCLC.

For more information about this project, please contact Janelle Schrag, MPH, Assistant Director of Research Programs, ACCC Provider Education.

Biomarker Testing Implementation Roadmap for Advanced NSCLC

This innovative learning tool can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.

Amy Jo Pixley"Deciding how best to develop and implement a new process requires a vision, a strategic plan, and a team devoted to the success of the project. By designing a concise visual representation of biomarker testing, this Biomarker Testing Implementation Roadmap will arm oncology practices and programs with access to a preemptive blueprint detailing the action steps and resources necessary to carry the initiative from vision to reality."

Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T)

Oncology Nurse Navigator
Ann B. Barshinger Cancer Institute at Penn Medicine Lancaster General
Lancaster, PA

View Roadmap


Operational Pathways for Biomarker Testing in NSCLC Environmental Scan

operational-pathways-nsclc-environmental-scan ThumbnailThis environmental scan provides an overview of the current landscape of biomarker testing at cancer programs, challenges or barriers to implementing testing recommendations, efforts by ACCC and others to-date, and possible solutions toward creating operational efficiencies in testing.
Download Environmental Scan




Our Partners

amp-200x80 lungevity-200x80

Our Supporter

This project is sponsored by Amgen.